525 related articles for article (PubMed ID: 31708096)
1. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
Mu X; Bai L; Xu Y; Wang J; Lu H
Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
[TBL] [Abstract][Full Text] [Related]
3. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
[TBL] [Abstract][Full Text] [Related]
5. BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes.
Ma L; Wang J; Zhang Y; Fang F; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Sang X; Zhang K; Lu L; Wan X; Chen Y; Yu J; Zhuo R; Wu S; Lu J; Pan J; Hu S
Cancer Biol Ther; 2022 Dec; 23(1):1-15. PubMed ID: 36170346
[TBL] [Abstract][Full Text] [Related]
6. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
[TBL] [Abstract][Full Text] [Related]
7. Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.
Liu S; Yosief HO; Dai L; Huang H; Dhawan G; Zhang X; Muthengi AM; Roberts J; Buckley DL; Perry JA; Wu L; Bradner JE; Qi J; Zhang W
J Med Chem; 2018 Sep; 61(17):7785-7795. PubMed ID: 30125504
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation.
Tao YF; Li ZH; Du WW; Xu LX; Ren JL; Li XL; Fang F; Xie Y; Li M; Qian GH; Li YH; Li YP; Li G; Wu Y; Feng X; Wang J; He WQ; Hu SY; Lu J; Pan J
Oncol Rep; 2017 Mar; 37(3):1419-1429. PubMed ID: 28184925
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
Zhou B; Hu J; Xu F; Chen Z; Bai L; Fernandez-Salas E; Lin M; Liu L; Yang CY; Zhao Y; McEachern D; Przybranowski S; Wen B; Sun D; Wang S
J Med Chem; 2018 Jan; 61(2):462-481. PubMed ID: 28339196
[TBL] [Abstract][Full Text] [Related]
11. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC.
Wang H; Tao Z; Feng M; Li X; Deng Z; Zhao G; Yin H; Pan T; Chen G; Feng Z; Li Y; Zhou Y
Biochem Biophys Res Commun; 2020 Dec; 533(3):368-375. PubMed ID: 32962858
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
Münch C; Dragoi D; Frey AV; Thurig K; Lübbert M; Wäsch R; Bogatyreva L; Hauschke D; Lassmann S; Werner M; May AM
Leuk Res; 2015 Apr; 39(4):462-70. PubMed ID: 25697066
[TBL] [Abstract][Full Text] [Related]
13. RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients.
Kolosenko I; Goroshchuk O; Vidarsdottir L; Björklund AC; Dowdy SF; Palm-Apergi C
FASEB J; 2021 May; 35(5):e21476. PubMed ID: 33788972
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
15. Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative.
Zhang J; Chen P; Zhu P; Zheng P; Wang T; Wang L; Xu C; Zhou J; Zhang H
Bioorg Chem; 2020 Jun; 99():103817. PubMed ID: 32361153
[TBL] [Abstract][Full Text] [Related]
16. Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells.
Wang NN; Li ZH; Zhao H; Tao YF; Xu LX; Lu J; Cao L; Du XJ; Sun LC; Zhao WL; Xiao PF; Fang F; Su GH; Li YH; Li G; Li YP; Xu YY; Zhou HT; Wu Y; Jin MF; Liu L; Ni J; Wang J; Hu SY; Zhu XM; Feng X; Pan J
Int J Mol Sci; 2015 Jan; 16(1):1266-92. PubMed ID: 25574601
[TBL] [Abstract][Full Text] [Related]
17. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
18. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
[TBL] [Abstract][Full Text] [Related]
19. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
[TBL] [Abstract][Full Text] [Related]
20. Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia.
Kannan S; Aitken MJL; Herbrich SM; Golfman LS; Hall MG; Mak DH; Burks JK; Song G; Konopleva M; Mullighan CG; Chandra J; Zweidler-McKay PA
Mol Cancer Ther; 2019 Sep; 18(9):1615-1627. PubMed ID: 31227645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
